Israel Englander’s Travere Therapeutics TVTX Stock Holding History

Israel Englander’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-20,000	Closed	-$594K	–	6419
2026 Q1	$594K	Sell	20,000 -90,000	-82%	-$2.69M	﹤0.01%	4675
2025 Q4	$4.2M	Buy	110,000 +9,500	+9%	+$309K	﹤0.01%	3200
2025 Q3	$2.4M	Buy	+100,500	New	+$1.89M	﹤0.01%	3867
2023 Q4	–	Sell	-266,100	Closed	-$2.38M	–	6554
2023 Q3	$2.38M	Buy	+266,100	New	+$3.75M	﹤0.01%	3392

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Israel Englander's TVTX Position: Q2 2026 in Review

Israel Englander opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 84,713 shares worth $4.81M. The stake represents ﹤0.01% of the portfolio and ranks #3030 among its holdings. This is a return to the name: Israel Englander previously reported a position in TVTX as recently as Q4 2025.

Israel Englander first reported a position in TVTX in Q1 2014 and has held it in 46 quarters since. The position peaked at $30M in Q3 2023. 317 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Israel Englander held 84,713 shares of Travere Therapeutics worth $4.81M as of Q2 2026.
Travere Therapeutics was a new Israel Englander position in Q2 2026.
Travere Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3030 holding.
Israel Englander first reported a position in Travere Therapeutics in Q1 2014 and has held it in 46 quarters since.
Israel Englander's Travere Therapeutics position peaked at $30M in Q3 2023.
317 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.